Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2023 Annual Meeting | N6 - Neuroscience in the Clinic: Myasthenia Gravis: From Pathogenesis to Targeted Therapies

Thursday 04/27/23
03:30 PM - 05:30 PM EST Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Neuroscience in the Clinic Session
A. Gordon Smith, MD, FAAN, Richard J. Nowak, MD
Neuromuscular and Clinical Neurophysiology (EMG)
Participants should gain an understanding of the immunopathologic mechanisms leading to weakness in myasthenia gravis, and be able to list newly FDA-approved myasthenia gravis treatments and define their mechanisms of action. Participants should also understand knowledge gaps in the therapeutic approach to myasthenia gravis and potential means of bridging them.

This program is supported in part by an educational grant from argenx US Inc.

The Academy was solely responsible, with no influence from the industry supporter, for selection of content, format, presenters, and moderators of this CME program, and the speakers have not been contacted or influenced in any way by the industry supporter with regard to this CME program.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Advanced
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student
Didactic

Program Materials Program Evaluations

Event Timeline
03:30 PM - 03:40 PM EST Introduction Introduction
A. Gordon Smith, MD, FAAN
03:40 PM - 04:00 PM EST Speaker Myasthenia Gravis: Immunopathology and Mechanisms of Disease
Kevin O'Connor
04:00 PM - 04:15 PM EST Abstract 001 - CD8 T Cell Immune Signatures in Autoimmune Myasthenia Gravis
Yingkai Li, MD, PhD
04:15 PM - 04:35 PM EST Speaker The Myasthenia Gravis Therapeutic Pipeline: Current and Future Targeted Approaches
Richard J. Nowak, MD
04:35 PM - 04:50 PM EST Abstract 002 - Application of a Validated Algorithm to Identify and Describe Contemporary Epidemiology of Privately Insured Myasthenia Gravis Patients in the United States
Amanda C. Guidon, MD
04:50 PM - 05:10 PM EST Speaker Personalized, Even If Not Yet Precision, Therapy for Myasthenia Gravis
Michael G. Benatar, MBChB, DPhil, FAAN
05:10 PM - 05:30 PM EST Discussion Q&A
A. Gordon Smith, MD, FAAN, Richard J. Nowak, MD, Kevin O'Connor, Michael G. Benatar, MBChB, DPhil, FAAN
Faculty Disclosures
Vern C. Juel, MD, FAAN Dr. Juel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Juel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Juel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Accordant Health Services. Dr. Juel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. The institution of Dr. Juel has received research support from argenx. The institution of Dr. Juel has received research support from Alexion. The institution of Dr. Juel has received research support from Janssen. The institution of Dr. Juel has received research support from NIH Rare Diseases Network.
A. Gordon Smith, MD, FAAN Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz. Dr. Smith has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Eidos. Dr. Smith has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Lexicon. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of Dr. Smith has received research support from NIH (NINDS, NIDDK). Dr. Smith has received publishing royalties from a publication relating to health care. Dr. Smith has received personal compensation in the range of $0-$499 for serving as a Study Section with NIH.
Michael G. Benatar, MBChB, DPhil, FAAN Dr. Benatar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Benatar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arrowhead. Dr. Benatar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Annexon. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UniQure. Dr. Benatar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cartesian. Dr. Benatar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Benatar has received intellectual property interests from a discovery or technology relating to health care.
Kevin O'Connor Kevin O'Connor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Kevin O'Connor has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Kevin O'Connor has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viela Bio. Kevin O'Connor has stock in Cabaletta.
Richard J. Nowak, MD Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Momenta . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viela Bio. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cour Pharma. The institution of Dr. Nowak has received research support from Ra Pharma. The institution of Dr. Nowak has received research support from Alexion . The institution of Dr. Nowak has received research support from Momenta . The institution of Dr. Nowak has received research support from Immunovant . Dr. Nowak has received research support from argenx. Dr. Nowak has received research support from Viela Bio . Dr. Nowak has a non-compensated relationship as a Member of the Board of Directors with Myasthenia Gravis Foundation of America (MGFA) that is relevant to AAN interests or activities.
Jeff Guptill, MD, FAAN Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx.
Amanda C. Guidon, MD An immediate family member of Dr. Guidon has received personal compensation for serving as an employee of GE Healthcare. Dr. Guidon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Guidon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. Dr. Guidon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Guidon has received research support from MGFA. The institution of Dr. Guidon has received research support from Project Data Sphere. The institution of Dr. Guidon has received research support from MGNet. The institution of Dr. Guidon has received research support from MGNet. Dr. Guidon has received publishing royalties from a publication relating to health care.
Yingkai Li, MD, PhD The institution of Dr. Li has received research support from Myasthenia Gravis Foundation of America.
Simon Gregory The institution of Simon Gregory has received research support from NIH. Simon Gregory has received intellectual property interests from a discovery or technology relating to health care. Simon Gregory has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant with David H Murdock Research Institute.
Tabitha Karatz Ms. Karatz has nothing to disclose.
Yevgeniy Semenov, MD Dr. Semenov has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Regeneron. Dr. Semenov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Galderma. Dr. Semenov has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of the American Academy of Dermatology. The institution of Dr. Semenov has received research support from Dermatology Foundation.
Yining Hua, Other Miss Hua has nothing to disclose.
Vera W. George, RN Mrs. George has nothing to disclose.